Physician profile
Manmeet Brar
NPI 1043285471
$2,233.54
in general payments reported to CMS, 2019-2025
24 companies · $52.19 in 2025
The $52.19 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $190 · 2021: $657 · 2022: $236 · 2023: $375 · 2024: $254 · 2025: $52.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663 · Education: $18.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $662.84 |
| Education | $18.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $464.03 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $195.47 | 2019-2024 | Velphoro |
| Vifor Pharma, INC. | $195.10 | 2019-2023 | Korsuva, Veltassa |
| Horizon Therapeutics Plc | $180.67 | 2019-2022 | |
| Akebia Therapeutics INC | $168.96 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $120.85 | 2019-2023 | Jynarque |
| Mallinckrodt Hospital Products INC. | $108.94 | 2020-2024 | Terlivaz, Acthar |
| Travere Therapeutics, INC. | $108.15 | 2023-2024 | |
| Glaxosmithkline, LLC. | $102.61 | 2023-2024 | Benlysta, Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $102.02 | 2021-2024 | |
| Medtronic, INC. | $84.79 | 2024 | Ellipsys Vascular Access System |
| Aurinia Pharma U.S., INC. | $53.33 | 2021 | |
| Genzyme Corporation | $50.30 | 2021-2022 | |
| Amicus Therapeutics, INC. | $47.59 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $38.66 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $29.42 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.35 | 2022 | |
| Lilly USA, LLC | $29.04 | 2024 | Jardiance |
| Mallinckrodt Enterprises LLC | $27.95 | 2019 | |
| Amgen INC. | $23.77 | 2019 | |
| Angiodynamics, INC. | $23.13 | 2020 | |
| Novo Nordisk INC | $21.45 | 2025 | |
| Phathom Pharmaceuticals, INC. | $15.90 | 2025 | Voquezna |
| Chiesi USA, INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manmeet Brar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.